Skin rash medication allergy is one of the most common adverse drug reactions encountered in clinical practice, ranging from a mild, self-limiting maculopapular eruption to life-threatening conditions such as Stevens–Johnson syndrome. Understanding why these reactions occur, which medicines most frequently cause them, and how to distinguish a true immune-mediated allergy from a non-allergic drug reaction is essential for safe prescribing and patient care. This guide covers the mechanisms behind drug-induced skin rashes, how they are diagnosed on the NHS, and the treatment and management options available to patients in the UK.

How Medication Allergies Can Cause a Skin Rash

Medication allergies cause skin rashes when the immune system mistakenly identifies a drug as harmful, releasing histamine and inflammatory mediators; reactions may be IgE-mediated (rapid) or T-cell mediated (delayed), and not every drug rash represents a true allergy.

Not sure if this is normal? Chat with one of our pharmacists →

A skin rash caused by a medication allergy occurs when the immune system mistakenly identifies a drug — or one of its metabolites — as a harmful foreign substance. In response, the immune system mounts a defensive reaction, releasing chemicals such as histamine and other inflammatory mediators that manifest visibly on the skin. This process is distinct from a predictable side effect; it is an immunologically mediated response that can occur even at standard therapeutic doses.

There are several immunological mechanisms involved. Type I hypersensitivity reactions (IgE-mediated) tend to occur rapidly, often within minutes to an hour of taking a medicine, and can produce urticaria (hives) or angioedema. On re-exposure to the same drug, reactions may occur more quickly than on first exposure. Type IV hypersensitivity reactions (T-cell mediated) are delayed, typically appearing 48–72 hours or even days after exposure, and are responsible for many maculopapular drug eruptions. Other mechanisms, including immune complex deposition and cytotoxic reactions, can also produce cutaneous manifestations.

It is important to understand that drug hypersensitivity reactions can be either immune-mediated (true allergy) or non-immune-mediated. Two clinically important non-immune examples are NSAID-exacerbated urticaria and angioedema (driven by COX-1 inhibition rather than IgE) and ACE inhibitor-induced angioedema (driven by bradykinin accumulation rather than an allergic mechanism). These have different management implications and should not be labelled as allergies in the conventional sense.

Not every rash that appears during a course of medication is a true allergic reaction. Some rashes are pharmacological side effects, viral exanthems coinciding with antibiotic use, or non-immune drug intolerances. Distinguishing between these possibilities is clinically significant, as mislabelling a reaction as an allergy can unnecessarily restrict future treatment options. A thorough clinical assessment is therefore essential before any allergy label is applied to a patient's medical record.

Experiencing these side effects? Our pharmacists can help you navigate them →

Relevant guidance: NICE CG183: Drug allergy — diagnosis and management; NHS: Drug allergies.

Common Medicines Linked to Allergic Skin Reactions

Penicillins, NSAIDs, anticonvulsants, and allopurinol are among the most common causes of allergic skin reactions; ACE inhibitor-associated angioedema is bradykinin-mediated rather than allergic and requires permanent drug discontinuation.

Several classes of medicines are more frequently associated with allergic skin reactions than others. Understanding which drugs carry a higher risk can help both patients and clinicians remain vigilant.

Antibiotics are among the most common culprits. Penicillins (such as amoxicillin and flucloxacillin) and cephalosporins are well-recognised causes of drug rashes, ranging from mild maculopapular eruptions to severe reactions. Sulphonamides, including co-trimoxazole, are also frequently implicated. Notably, amoxicillin given during infectious mononucleosis (glandular fever) commonly produces a widespread maculopapular rash — this is not a true allergy but is often mistakenly recorded as one.

Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, can trigger urticaria and angioedema. In many cases this reflects COX-1–mediated cross-intolerance rather than a true IgE-mediated allergy, meaning cross-reactivity across different NSAIDs is common. Paracetamol or, in some cases, COX-2 selective inhibitors may be considered as alternatives under clinical guidance.

Anticonvulsants — including carbamazepine, lamotrigine, and phenytoin — are associated with a spectrum of reactions from mild rashes to life-threatening conditions such as Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalised exanthematous pustulosis (AGEP). Allopurinol, used in gout management, is one of the most common causes of severe cutaneous adverse reactions (SCARs) in the UK; the risk is higher in individuals of certain ethnic backgrounds (for example, those carrying the HLA-B*58:01 allele, more prevalent in some East and South-East Asian populations) — clinicians should follow current MHRA and SmPC cautions.

Other medicines to be aware of include:

• ACE inhibitors (e.g., ramipril, lisinopril) — associated with angioedema that is bradykinin-mediated, not allergic. This can occur weeks, months, or even years after starting the medicine and may not respond to antihistamines or adrenaline. Any episode of ACE inhibitor-associated angioedema warrants permanent discontinuation of the ACE inhibitor, and the reaction should not be labelled as a drug allergy. An MHRA Drug Safety Update addresses this risk.

• Biologics and monoclonal antibodies — can cause injection-site reactions and systemic rashes

• Contrast media used in radiology — may provoke urticarial reactions

• Chemotherapy agents — frequently cause a range of cutaneous effects

Patients should always inform their healthcare provider of any previous reactions to medicines, however mild they may have seemed at the time.

Relevant guidance: MHRA Drug Safety Update: ACE inhibitors and risk of angioedema; MHRA Drug Safety Update: Allopurinol — risk of severe cutaneous adverse reactions; emc SmPCs for individual medicines.

Recognising Symptoms: From Mild Rashes to Severe Reactions

Drug rashes range from mild maculopapular eruptions and urticaria to life-threatening conditions such as SJS and TEN; blistering, skin pain, mucosal involvement, and fever are red-flag features requiring immediate medical attention.

Drug-induced skin reactions present across a wide clinical spectrum, and recognising the pattern and severity of a rash is crucial for appropriate management.

Mild to moderate reactions commonly include:

• Maculopapular (morbilliform) rash — flat or slightly raised red spots, often starting on the trunk and spreading outwards; typically appears 7–14 days after starting a new medicine

• Urticaria (hives) — raised, itchy wheals that may appear and disappear rapidly; can occur anywhere on the body

• Fixed drug eruption — a well-demarcated, round, dusky-red patch that recurs in the same location each time the offending drug is taken

More serious reactions require urgent recognition:

• Angioedema — deep swelling of the skin, lips, tongue, or throat; potentially life-threatening if the airway is compromised

• Acute generalised exanthematous pustulosis (AGEP) — characterised by rapid onset of widespread small pustules on a red background, accompanied by fever; typically resolves quickly once the causative drug is stopped

• Drug reaction with eosinophilia and systemic symptoms (DRESS) — a severe, delayed reaction presenting with widespread rash, fever, lymphadenopathy, and internal organ involvement (liver, kidneys, lungs); typically occurs 2–8 weeks after starting the causative drug

• Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) — rare but life-threatening conditions characterised by widespread blistering, skin detachment, and mucosal involvement (eyes, mouth, genitals); these constitute dermatological emergencies

Key warning features that suggest a severe reaction include:

• Blistering or skin peeling

• Skin pain or tenderness (an early warning sign of SJS/TEN)

• Early mucosal symptoms — sore, red, or crusted eyes; soreness or ulceration of the mouth or lips

• Facial swelling

• Fever

• A rapidly spreading rash

Any of these features should prompt immediate medical attention. The timing of symptom onset relative to starting a new medicine is an important diagnostic clue and should always be noted.

Relevant guidance: NHS: Stevens–Johnson syndrome and toxic epidermal necrolysis; British Association of Dermatologists (BAD) patient information on drug rashes and SCARs.

When to Seek Medical Help or Call 999

Call 999 immediately if a drug rash is accompanied by swelling of the throat, difficulty breathing, widespread blistering, or skin pain, as these may indicate anaphylaxis or a severe cutaneous adverse reaction.

Knowing when to escalate care is one of the most important aspects of managing a suspected medication allergy. Not all drug rashes require emergency treatment, but certain features demand immediate action.

Call 999 or go to your nearest A&E immediately if you or someone else experiences:

• Swelling of the lips, tongue, throat, or face (angioedema)

• Difficulty breathing, wheezing, or a tight chest

• Dizziness, collapse, or loss of consciousness

• Widespread blistering or skin peeling

• Skin pain or tenderness, or soreness affecting the eyes or mouth alongside a rash

• A rapidly spreading rash accompanied by high fever

These symptoms may indicate anaphylaxis or a severe cutaneous adverse reaction such as SJS or TEN, both of which are medical emergencies.

If anaphylaxis is suspected:

• Use an adrenaline auto-injector (such as an EpiPen) immediately if one is available

• Lie down with legs raised, unless breathing is difficult — in that case, sit upright

• Do not stand up

• If there is no improvement after 5 minutes, use a second adrenaline auto-injector if available

• Emergency services should be called regardless of whether an auto-injector has been used

Consistent with Resuscitation Council UK guidance on emergency treatment of anaphylaxis.

Contact your GP or NHS 111 promptly if:

• A new rash develops shortly after starting a medicine and is spreading

• The rash is accompanied by joint pain, fever, or swollen glands

• You are unsure whether to continue taking the medicine

• The rash is causing significant discomfort or distress

Important advice on stopping medicines: Do not take any further doses of the medicine you suspect has caused the reaction, and seek medical advice promptly. If severe features are present (such as blistering, mucosal involvement, skin pain, or breathing difficulty), stop the suspected medicine immediately and call 999. However, do not stop other prescribed medicines — particularly anticonvulsants or cardiovascular drugs — without first seeking medical advice, as abrupt discontinuation may carry its own risks. A clinician can advise on whether it is safe to switch to an alternative or stop a medicine under supervision.

Reporting suspected reactions: Both patients and healthcare professionals can report suspected adverse drug reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app. Reporting helps improve medicine safety for everyone.

Relevant guidance: NHS: Anaphylaxis; Resuscitation Council UK: Emergency treatment of anaphylaxis; MHRA Yellow Card Scheme.

Diagnosis and Testing on the NHS

NHS diagnosis of drug allergy is led by detailed clinical history; specialist testing may include skin prick testing, specific IgE assays, patch testing, or supervised drug provocation testing, with drug provocation contraindicated after severe reactions such as SJS or TEN.

Diagnosing a drug allergy accurately is important both for patient safety and to avoid unnecessary restriction of future treatment options. The NHS and NICE guidance (CG183: Drug allergy — diagnosis and management) provide a structured framework for assessment.

Initial evaluation involves a detailed clinical history, which remains the cornerstone of diagnosis. Clinicians will typically ask about:

• The specific medicine(s) involved, the dose, and the route of administration

• The timing of the reaction relative to starting the drug

• The nature, distribution, and progression of the rash

• Any previous reactions to the same or related medicines

• Concurrent illnesses or other medicines taken at the time

• The severity of the reaction and any treatment required

For immediate-type reactions (IgE-mediated), skin prick testing and intradermal testing can be performed by specialist allergy services to identify sensitisation to specific drugs, most commonly penicillins. Specific IgE blood tests (immunoassays) are available for some medicines but have limited availability for many drugs and variable sensitivity; the older term 'radioallergosorbent test (RAST)' is now largely obsolete.

For delayed reactions, patch testing may be used, particularly for contact-type hypersensitivity. In some cases, a supervised drug provocation test (DPT) — where the suspected drug is administered under controlled conditions — may be the most reliable way to confirm or exclude an allergy. This is typically carried out in a specialist setting. Drug provocation testing is contraindicated after severe cutaneous adverse reactions such as SJS, TEN, or DRESS, given the risk of a life-threatening recurrence. Testing is generally deferred until several weeks after full resolution of the acute reaction to improve both accuracy and safety.

NICE recommends that all patients with a suspected drug allergy should have the reaction clearly documented in their medical records, including the drug name, dose, route, timing, nature of the reaction, severity, and the level of certainty of the diagnosis. Referral to a specialist allergy clinic should be considered for patients with a history of severe reactions, those requiring the suspected drug for ongoing treatment, or where the diagnosis remains uncertain.

Healthcare professionals and patients can report suspected adverse drug reactions to the MHRA via the Yellow Card scheme (yellowcard.mhra.gov.uk).

Relevant guidance: NICE CG183: Drug allergy — diagnosis and management; BSACI guideline on beta-lactam antibiotic allergy assessment and de-labelling; MHRA Yellow Card Scheme.

Treatment Options and Managing Future Medication Use

Treatment begins with stopping the suspected drug; mild reactions are managed with antihistamines or topical corticosteroids, while severe reactions such as SJS or DRESS require urgent hospital admission and the allergy must be clearly documented in NHS records.

The management of a skin rash caused by a medication allergy depends on the severity of the reaction, the importance of the causative drug, and the availability of suitable alternatives.

Stopping the suspected medicine is a critical first step. Do not take any further doses of the suspected causative drug; for severe cutaneous adverse reactions (SCARs) such as SJS, TEN, or DRESS, immediate withdrawal is essential and may influence outcomes.

For mild to moderate reactions, symptom management may include:

• Urticaria — oral antihistamines such as cetirizine or loratadine are effective for itch and wheals

• Maculopapular (morbilliform) rash — antihistamines have limited benefit for the rash itself; emollients may soothe dry or irritated skin, and topical corticosteroids (e.g., hydrocortisone cream for mild cases, or a moderately potent preparation as directed by a clinician) can help reduce localised inflammation and itch

• For more widespread or persistent rashes, a short course of oral corticosteroids may be prescribed by a GP or specialist

For severe reactions such as DRESS, SJS, or TEN, urgent hospital admission is required, often to a specialist burns unit or intensive care setting, with multidisciplinary input including dermatology, ophthalmology, and critical care. Treatment is largely supportive — involving wound care, fluid management, nutritional support, and eye care. Systemic immunosuppression may be considered in some cases, though evidence for specific agents remains an area of ongoing research.

Looking ahead, managing future medication use is a critical component of care:

• The causative drug should be clearly documented as an allergy (or adverse reaction, as appropriate) in the patient's NHS records, with the reaction type, severity, and certainty level specified

• Patients should be advised to inform all healthcare providers — including dentists and pharmacists — of their allergy or adverse reaction history

• A MedicAlert bracelet or similar alert system may be recommended for those with a history of severe reactions

• Where the causative drug is essential and no suitable alternative exists (e.g., penicillin for a serious infection), drug desensitisation may be considered in a specialist centre; this involves administering gradually increasing doses under close supervision to induce temporary tolerance only — it does not constitute a cure, and the allergy status returns once the course is complete. Desensitisation is reserved for situations where no effective alternative treatment is available.

It is worth emphasising that a confirmed drug allergy label has long-term implications. NICE guidance highlights that many patients labelled as penicillin-allergic are not truly allergic, and appropriate de-labelling through specialist assessment can safely restore access to first-line treatments, improving clinical outcomes and reducing the use of broader-spectrum antibiotics.

Report suspected adverse drug reactions — including skin reactions to medicines — via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app. This applies to both patients and healthcare professionals.

Relevant guidance: NICE CG183: Drug allergy — diagnosis and management; BAD clinical guidance on SJS/TEN and SCARs; BSACI guideline on beta-lactam allergy de-labelling; MHRA Yellow Card Scheme.

Frequently Asked Questions